Table 1 Patient demographics and pathologic features
From: Clinical outcomes and prognostic factors for gastric cancer patients with bone metastasis
Factors | Patient (n = 34) | |
|---|---|---|
Age (years) | Median (range) | 66 (39–78) |
Gender | Male | 26 (76.5%) |
Female | 8 (23.5%) | |
ECOG performance status | 0–1 | 16 (47.1%) |
2–4 | 18 (52.9%) | |
Bone pain | Present | 11 (32.4%) |
Absent | 23 (67.6%) | |
Location | Upper 1/3 | 5 (14.7%) |
Middle 1/3 | 17 (50.0%) | |
Lower 1/3 | 5 (14.7%) | |
Whole stomach | 7 (20.6%) | |
Histologic type | Differentiated | 15 (44.1%) |
Undifferentiated | 19 (55.9%) | |
Stagea | I | 1 (2.9%) |
II | 3 (8.8%) | |
III | 8 (23.5%) | |
IV | 22 (64.7%) | |
Treatment for primary tumor | Surgery | 16 (47.1%) |
Chemotherapy | 18 (52.9%) | |
ALP (IU/L) | Median (range) | 375.5 (157–2743) |
LDH (IU/L) | Median (range) | 249 (117–1481) |
CEA | Median (range) | 8.6 (1.0–3508) |
CA19-9 | Median (range) | 53.7 (0.6–1814.0) |
CA125 | Median (range) | 20.3 (7.9–1099) |
Diagnostic modality | CT | 30 (88.2%) |
Bone scan | 10 (29.4%) | |
MRI | 9 (26.5%) | |
PET-CT | 1 (2.9%) | |
Pattern of bone metastasis | Synchronous | 10 (29.4%) |
Metachronous | 24 (70.6%) | |
Number of bone metastases | Single | 12 (35.3%) |
Multiple | 22 (64.7%) | |
Extraosseous metastasis | Present | 26 (76.5%) |
Absent | 8 (23.5%) | |
Treatment of bone metastasis | Chemotherapy | 26 (76.5%) |
Radiotherapy | 5 (14.7%) | |
Best supportive care | 4 (11.8%) |